Abstract:Background: In recent years, immunotherapy has changed the therapeutic landscape of hepatocellular carcinoma (HCC). Since the efficacy of immunotherapy is closely related to the tumor microenvironment (TME), in this study, we constructed a prognostic model based on TME to predict the prognosis and immunotherapy effect of HCC patients. Methods: Transcriptome and follow-up data of 374 HCC patients were acquired from the TCGA Cancer Genome Atlas (TCGA) database. The immune/stromal/estimate scores (TME scores) and tumor purity were calculated using the ESTIMATE algorithm and the module most associated with TME scores were screened by the weighted gene co-expression network analysis (WGCNA). A TME score-related prognostic model was constructed and patients were divided into a high-risk group and a low-risk group. Kaplan-Meier survival curves and receiver operator characteristic curve (ROC) were used to evaluate the performance of the TME risk prognostic model and validated with the external database International Cancer Genome Consortium (ICGC) cohort. Combined with clinicopathologic factors, a prognostic nomogram was established. The nomogram's ability to predict prognosis was assessed by ROC, calibration curve, and the decision curve analysis (DCA). Gene Set Enrichment Analyses (GSEA) were conducted to explore the underlying biological functions and pathways of this risk signature. Moreover, the possible correlation of risk signature with TME immune cell infiltration, immune checkpoint inhibitor (ICI) treatment response, single-nucleotide polymorphisms (SNPs), and drug sensitivity were assessed. Finally, real-time PCR was used to verify the gene expression levels in normal liver cells and cancer cells. Results: KM survival analysis results indicated that high immune/stromal/estimate score groups were closely associated with a better prognosis, while the tumor purity showed a reverse trend ( p < 0.01). WGCNA demonstrated that the yellow module was significantly correlated with the TME score. The 5-genes TME risk signature was built to predict the prognosis of patients with HCC including DAB2 , IL18RAP , RAMP 3, FCER1G , and LHFPL2 . Patients with a low-risk score have higher levels of tumor-infiltrating immune cells and higher expression of immune checkpoints, which may be more sensitive to immunotherapy. Conclusion: It provided a theoretical basis for predicting the prognosis and personalized treatment of patients with HCC.

A Robust Prognostic Signature of Tumor Microenvironment in Colorectal Cancer.

A Hot and Cold Tumor‑related Prognostic Signature for Stage II Colorectal Cancer

Identification of a Tumor Microenvironment-Related Gene Signature Indicative of Disease Prognosis and Treatment Response in Colon Cancer

Identification of tumor microenvironment-related prognostic genes in colorectal cancer based on bioinformatic methods

Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer

Prognostic Risk Model of Immune-Related Genes in Colorectal Cancer

Identification of Prognostic Immune-Related Gene Signature Associated with Tumor Microenvironment of Colorectal Cancer

Identification and validation of an immune prognostic signature in colorectal cancer

Profiling of Tumor Microenvironment Components Identifies Five Stroma-Related Genes with Prognostic Implications in Colorectal Cancer.

A tumor microenvironment gene set-Based prognostic signature for non-small-cell lung cancer

A New Prognostic and Therapeutic Immune-related Risk Signature of Colorectal Cancer

An Immune Landscape Based Prognostic Signature Predicts the Immune Status and Immunotherapeutic Responses of Patients with Colorectal Cancer.

Prognostic Signatures Based on Thirteen Immune-Related Genes in Colorectal Cancer

Identification of Prognostic Gene Signature Associated with Tumor Microenvironment of Cholangiocarcinoma

Exploration and validation of a combined immune and metabolism gene signature for prognosis prediction of colorectal cancer

Identification of a basement membrane-related gene signature for predicting prognosis, immune infiltration, and drug sensitivity in colorectal cancer

Construction of a prognostic signature associated with liver metastases for prognosis and immune response prediction in colorectal cancer

Identification of Prognostic Immune-Related Signature Predicting the Overall Survival for Colorectal Cancer

A Mutational Signature That Predicts Prognosis and Benefit of Immune Checkpoint Blockade in Colorectal Cancer

A Novel Prognostic Signature Associated With the Tumor Microenvironment in Kidney Renal Clear Cell Carcinoma

Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma